AUTHORS
Vipul Sheth, MD DM, Deepam Pushpam, MD2, Dr Gauri Kapoor, MD DM3, Sameer Bakhshi, MD4, Sandip Shah, MD DM5, Sanket Shah, MD6, Branko Cuglievan, MD7, Rajnita Ingavale, MS8, Divyesh Mandavia, MD9, Ashokkumar Thakkar10, Aaman Bilakhia11, Arnon Nagler I, MD12, Dinesh Pendharkar, MD,PhD,FASCO13, Naval Daver, MD14
AFFILIATIONS
1 Rajiv Gandhi Cancer Institute & Research Centre, New Delhi, India
2 All India Institute of Medical Sciences (AIIMS), New Delhi, India
3 Rajiv Gandhi Cancer Institute & Research Centre, New Delhi, India
4 All India Institute of Medical Sciences (AIIMS), New Delhi, India
5 HOC Vedanta (Cellcure Cancer Centre Pvt Ltd), Ahmedabad, Gujarat, India
6 HOC Vedanta (Cellcure Cancer Centre Pvt Ltd), Ahmedabad, Gujarat, India
7 MD Anderson Cancer Center, Texas, Texas, United States
8 Meril Life Sciences Pvt. Ltd., Ahmedabad, Gujarat, India
9 Micro CRISPR Pvt. Ltd, Ahmedabad, Gujarat, India
10 Meril Life Sciences Pvt. Ltd., Ahmedabad, Gujarat, India
11 Meril Life Sciences Pvt. Ltd., Vapi, Gujarat, India
12 Chaim Sheba Medical Center, Tel HaShomer, Israel, Tel HaShomer, Israel
13 Sarvodaya Cancer Institute (Sarvodaya Hospital), Faridabad, India
14 MD Anderson Cancer Center, Texas, Texas, United States
ABSTRACT
Introduction
Naricabgene autoleucel (Nari-cel; MyCART-01; MYCARTTM) is a first in human third-generation, autologous CD19-directed CAR-T cell therapy, with a murine ScFV and importantly dual costimulatory domains (CD28 and 4-1BB). We report the phase I/II safety and efficacy results of nari-cel in patients (N=35) with relapsed/ refractory (R/R) B-cell Acute Lymphoblastic Leukemia (B-ALL) and Non-Hodgkin Lymphoma (NHL).
Methods
Eligible patients had CD19+ R/R B-ALL (≥5% blasts in marrow) or NHL with PET-CT measurable disease. Following 3-days of standard lymphodepletion (cyclophosphamide 500 mg/m2 and fludarabine 30mg/m2) with 2-days rest, patients received nari-cel at 2 x106 to 5 x106 CAR-T cells/kg as assigned during the Phase I dose finding part.
The primary endpoints were safety through Day 30 for Phase I, and ORR at day 30 for B-ALL (NCCN V.2.0.0, 2014 criteria) and month 3 for NHL (by PET-CT -Lugano 2014 criteria) for Phase II. Secondary/exploratory analyses included measurable residual disease (MRD by multiparametric flow cytometry; sensitivity of ≤10-5), CAR-T kinetics, cytokine release syndrome (CRS) and Immune effector cell-associated neurotoxicity syndrome (ICANS), immune effector related cytopenias, graded accordingly to ASTCT criteria.
Results
As of 20 July 2026, 35 patients had received nari-cel in India, including 19 patients with R/R B-ALL (16 adults, 3 pediatric patients) and 16 patients with R/R NHL. The median age was 30 years (72% male) in the B-ALL cohort and 49 years (69% male) in the NHL cohort. Among NHL patients (N=16), histology included DLBCL (n=14), PMBCL (n=1) and tFL (n=1). Among 19 patients with B-ALL, 31.6% (6/19) had Philadelphia chromosome+ disease. The median (range) of prior lines of therapies was 2 (1-4) and 2 (1-5) for B-ALL and NHL, respectively. Three (19%) NHL patients had prior autologous stem cell transplantation, and 31 patients (89%) received bridging therapy.
Ten patients received 2 x106 CAR-T cells/kg (5 B-ALL, 5 NHL; including 1 NHL at 3 x106 CAR-T cells/kg) and 25 received 5 x106 CAR-T cells/kg (14 B-ALL, 11 NHL). Median (IQR) follow-up is 12.7 months (9.8, 17.4) and 11.4 months (8.9, 17.1) for B-ALL and NHL, respectively.
CRS occurred in 17/19 (89.5%) of B-ALL patients [≥ G3 in 7 (36.8%)] and 15/16 (93.8%) of NHL patients [≥ G3 in 2 (12.5%)]. ICANS occurred in 3/19 (15.8%) of B-ALL (G3 in 1; 5.3%) and 2/16 (12.5%) of NHL (≥ G3 in 1; 6.3%).
Hematologic toxicities (≥ G3) included neutropenia (34/35; 97.1%), thrombocytopenia (25/35; 71.4%), and anemia (21/35; 60%) with median recovery (at least to Grade 2) of 28, 32 and 8 days, respectively. No prolonged neutropenia or thrombocytopenia requiring continuous transfusion/ growth factor support observed. No treatment-related mortality was observed through Day +90. No major organ toxicity signals, no cases of CAR-T infusion reactions, tumor lysis syndrome, immune effector cell-associated hemophagocytic syndrome (HLH/IEC-HS), new autoimmune disorders or secondary malignancy reported.
All 35 infused patients were evaluable for efficacy. In R/R B-ALL, the ORR (CR/CRi) was 100% (19/19) with all responders achieving flow MRD (LLOD: 1 in 105) negativity. Two patients subsequently underwent consolidative allogeneic stem cell transplantation, one following development of lineage switch to abnormal undifferentiated stem cell population (at ?7.5 months) and one at the investigator's discretion (at 15 months) with sustained MRD-negative remission (post infusion of second CAR T cell infusion for CD19+ MRD positivity at one year). In R/R NHL, ORR was 87.5% (14/16; 75% CR). Median PFS was not reached in either cohort with overall median follow-up of 12.24 months. The estimated PFS rates at 12 months were 82.1% and 62.5% for B-ALL and B-NHL respectively. The OS at last follow up was 16/19 (84.2%) and 11/16 (68.8%) for B-ALL and NHL, respectively.
CAR transgene expansion peaked on Day 7, with a AUC0-30 of 1.61 million copies*day/ng of gDNA, followed by slow decline with persistence in 100% (5/5) till last assessed time-point of 15 months among evaluable patients. No anti-CAR antibodies were detected in study.
Conclusions
Naricabgene autoleucel demonstrated a manageable safety profile and robust efficacy in R/R B-ALL and NHL in heavily pretreated patients, resulting in accelerated regulatory approval in India. Long term follow-up is ongoing, and global multi-center studies are planned to support international regulatory approvals.
DISCLOSURES
Vipul Sheth, MD DM: MicroCRISPR Pvt. Ltd - Research Funding; Immuneel Therapeutics Private Limited - Consultancy (Includes expert testimony); MicroCRISPR Pvt. Ltd - Consultancy (Includes expert testimony)